Table 1 Baseline features, final diagnoses and outcome of 340 patients of the NIDIAG neurology cohort with available T. solium antigen results
Total participants evaluated (n = 340) | TS antigen negative participants (n = 297) | TS antigen positive participants (n = 43) | P | |
|---|---|---|---|---|
Features at presentation | n (%) | n (%) | n (%) | |
Male sex | 159 (46.8) | 137 (46.1) | 22 (51.2) | 0.5 |
Female sex | 181 (53.2) | 160 (53.8) | 21 (48.8) | 0.5 |
Age > 20 years | 270 (79.4) | 231 (77.8) | 39 (90.7) | 0.05 |
Prior contact with primary care facility | 159 (46.8) | 141 (47.5) | 18 (41.9) | 0.4 |
Neurological symptoms > two weeks | 190 (55.9) | 168 (56.6) | 22 (51.2) | 0.5 |
Fever reported/documented | 99 (29.1) | 89 (30.0) | 10 (23.3) | 0.3 |
Severe headache | 156 (45.9) | 136 (45.8) | 20 (46.5) | 0.9 |
Severe headache without fever | 101 (29.7) | 86 (29.0) | 15 (34.9) | 0.4 |
Gait/walking disorders | 97 (28.5) | 86 (29.0) | 11 (25.6) | 0.6 |
Seizure | 84 (24.7) | 73 (24.6) | 11 (25.6) | 0.8 |
Focal sensory-motor deficit | 77 (22.6) | 67 (22.6) | 10 (23.3) | 0.9 |
Cognitive and/or behavior disturbance | 72 (21.2) | 60 (20.2) | 12 (27.9) | 0.2 |
Altered state of consciousness | 69 (20.3) | 61 (20.5) | 8 (18.6) | 0.7 |
Final diagnoses | n (%) | n (%) | n (%) | |
Confirmed targeted infections | 84 (24.7) | 76 (25.6) | 8 (18.6) | 0.3 |
Confirmed and suspected infections | 119 (35.0) | 107 (36.0) | 12 (27.9) | 0.2 |
Non-communicable conditions | 156 (45.9) | 134 (45.1) | 22 (51.2) | 0.4 |
Epilepsy | 60 (17.6) | 51 (17.2) | 9 (20.9) | 0.5 |
Psychiatric disorders | 53 (15.6) | 47 (15.8) | 6 (14.0) | 0.7 |
Myelo-radiculo-neuropathic syndromes | 37 (10.9) | 30 (10.1) | 7 (16.3) | 0.2 |
Cerebrovascular accident | 23 (6.8) | 20 (6.7) | 3 (7.0) | 0.9 |
Outcome | n (%) | n (%) | n (%) | |
Death | 26 (7.6) | 23 (7.7) | 3 (7.0) | 0.8 |